GLP1 agonists set to become the best-selling drugs in 2024, says GlobalData
Go to source). GLP-1 agonists target the glucagon-like peptide 1 receptor (GLP-1R) found in the pancreas and brain neurons. They work by promoting insulin secretion, aiding in blood sugar level maintenance among type 2 diabetics, and facilitating weight loss by reducing appetite and delaying gastric emptying.
Weight Loss Drugs
Diet pills are medicines that help control or reduce weight. Diet pills are otherwise know as weight loss drugs or anti-obesity medications.
Diet pills are medicines that help control or reduce weight. Diet pills are otherwise know as weight loss drugs or anti-obesity medications.
‘GLP-1 agonists are anticipated to surpass PD-1 antagonists as the leading drugs on the market in 2024. #weightlossdrugs #diabetesdrugs’
Tweet it Now
Kevin Marcaida, Pharma Analyst at GlobalData, notes that while PD-1 antagonists currently dominate the market with $38.9 billion in sales, GLP-1 antagonist sales in 2023 present a more diversified landscape, driven primarily by drugs like Ozempic, Trulicity, and Mounjaro.
GLP-1 Agonist Market to Surge
Looking ahead, the GLP-1 agonist market is projected to experience robust growth, with a 19.2% compound annual growth rate (CAGR) from 2023 to 2029, reaching a market size of $105 billion in 2029. In contrast, the PD-1 antagonist market forecasts a slower growth rate, with a 4.7% CAGR and a market size of $51 billion in 2029.Leading the charge in the GLP-1 market are five key drugs: Mounjaro, Ozempic, Wegovy, Cagrisema, and Rybelsus, which are expected to capture 83% of the GLP-1 agonist market by 2029. Eli Lilly’s Mounjaro is predicted to lead in sales, generating $33.4 billion annually by 2029, with Novo Nordisk emerging as the leading company, projected to capture 55% of the market share in 2029.
Marcaida concludes that this transformative shift reflects changing demand away from oncology towards addressing metabolic disorders. As industry leaders such as Novo Nordisk and Eli Lilly drive this evolution, a reorientation in drug preferences is anticipated in the coming years.
Quiz on Diabetes Medications
How much do you know about the medications used to treat diabetes? Here are a few questions you could attempt to test your ...
How much do you know about the medications used to treat diabetes? Here are a few questions you could attempt to test your ...
- GLP-1 agonists set to become the best-selling drugs in 2024, says GlobalData - (https://www.globaldata.com/media/pharma/glp1-agonists-set-to-become-the-best-selling-drugs-in-2024-says-globaldata/)
Weight Loss Calculator
Weight Loss Calculator calculates calories needed to lose weight for men and women. Find out the amount of calories burned while doing exercises for weight loss and check the list of low calorie foods.
Weight Loss Calculator calculates calories needed to lose weight for men and women. Find out the amount of calories burned while doing exercises for weight loss and check the list of low calorie foods.
Diabetes and Obesity Market of GLP-1 Drugs Will Be $125 Billion By 2033!
GLP-1 drugs, the marvel drugs, in recent decades, have led the market significantly, with a market projection of $125 billion by 2033.
GLP-1 drugs, the marvel drugs, in recent decades, have led the market significantly, with a market projection of $125 billion by 2033.
